The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review
- 1 December 2006
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 42 (18) , 3127-3139
- https://doi.org/10.1016/j.ejca.2006.09.015
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancerEuropean Journal Of Cancer, 2005
- Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast CancerJournal of Clinical Oncology, 2005
- Plasma markers of angiogenesis in pregnancy induced hypertensionThrombosis and Haemostasis, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced CancerJournal of Clinical Oncology, 2001